Dana Bowers
Clinical Assistant Professor, Pharmacotherapy 509-249-7932 Cadwell 104 Yakima

Education

Doctor of Pharmacy, Washington State University
Bachelor of Arts in biology, Central Washington University

Fellowships & Additional Training

Clinical Research Fellowship in infectious diseases, University of Houston College of Pharmacy and Baylor St. Luke’s Medical Center in Houston, Texas

PGY-1 Residency at Providence St. Peter Hospital in Olympia, Wash.

Teaching

Bowers is currently a clinical assistant professor at the WSU College of Pharmacy Pharm.D. program extension located on the PNWU campus in Yakima.

Research

Bowers research interest is in combination therapy for multi-drug resistant Gram-negative bacteria.

Additional Information

Bowers is a member of the Society of Infectious Diseases Pharmacists.

Selected Publications

Bowers DR, Huang V. Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE).Curr Infect Dis Rep. 2016 Dec;18(12):48.

Diep JK, Jacobs DM, Sharma R, Covelli J, Bowers DR, Russo TA, Rao GG. Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017 Jan 24;61(2).

Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May;59(5):2720-5.

Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LD. Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother. 2015 May;59(5):2930-3.

Bowers DR, Hunter AS, Jacobs DM, Kuper KM, Musick WL, Perez KK, Shah DN, Schilling AN. Significant publications on infectious diseases pharmacotherapy in 2012.Am J Health Syst Pharm. 2013 Nov 1;70(21):1930-40.

Bowers DR, Tam VH. Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther. 2013 Aug;11(8):831-7.

Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2013 Mar;57(3):1270-4.

updated 07/26/2017